Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck eisai Co., Ltd. (Lenvima Oncology Alliance) — Commercialization / SG&A expense sharing ($M) ($M)
Form 10-Q / 10-K Note 3/4 Collaborative Arrangements
Latest, Q2 2026
29
Period ended Jun 30, 2026
Change on a year earlier
-17.1%
35 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Eisai Co., Ltd. (Lenvima Oncology Alliance) — Commercialization / SG&A expense sharing ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 29 | -17.1% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 27 | -12.9% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 35 | -10.3% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2025 | Sep 30, 2025 | 33 | -17.5% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 35 | -14.6% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2025 | Mar 31, 2025 | 31 | -20.5% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2024 | Dec 31, 2024 | 39 | -11.4% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 40 | -13.0% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 41 | -14.6% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 39 | -23.5% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 44 | +2.3% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2023 | Sep 30, 2023 | 46 | +9.5% | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 48 | +14.3% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2023 | Mar 31, 2023 | 51 | +64.5% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 43 | +10.3% | Form 10-K (filed 2025-02-25) ↗ |
| Q3 2022 | Sep 30, 2022 | 42 | +23.5% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 42 | +35.5% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 31 | +34.8% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2021 | Dec 31, 2021 | 39 | +56.0% | Form 10-K (filed 2024-02-26) ↗ |
| Q3 2021 | Sep 30, 2021 | 34 | +88.9% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 31 | +63.2% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 23 | +109.1% | Form 10-Q (filed 2022-05-05) ↗ |
| Q4 2020 | Dec 31, 2020 | 25 | +19.0% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2020 | Sep 30, 2020 | 18 | -14.3% | Form 10-Q (filed 2021-11-05) ↗ |
| Q2 2020 | Jun 30, 2020 | 19 | 0.0% | Form 10-Q (filed 2021-08-09) ↗ |
| Q1 2020 | Mar 31, 2020 | 11 | -42.1% | Form 10-Q (filed 2021-05-05) ↗ |
| Q4 2019 | Dec 31, 2019 | 21 | – | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2019 | Sep 30, 2019 | 21 | – | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 19 | – | Form 10-Q (filed 2020-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 19 | – | Form 10-Q (filed 2020-05-06) ↗ |
Cite this data
StockData. (2026). Merck Eisai Co., Ltd. (Lenvima Oncology Alliance) — Commercialization / SG&A expense sharing ($M) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab_eisai_sga
See every metric in the Merck KPI table. Data updated Oct 26, 2026.